Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs BIO-TECHNE Corp — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.32, while BIO-TECHNE Corp trades at $71.75 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | TECH | |
|---|---|---|
52-Week High | $97.99 | $72.12 |
52-Week Low | $93.11 | $43.31 |
Market Cap | — | $11.16B |
Sector | — | Health |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF (iShares 7-10 Year Treasury Bond ETF) trades at $93.54, down 0.32% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 58.33, while bond market uncertainty persists amid Federal Reserve policy speculation. Recent dividend payments of $0.31-$0.32 reflect steady income distribution to shareholders.
The outlook remains cautious as bond ETFs face pressure from potential rate hikes and inflation concerns. Investment opportunity lies in Treasury exposure for portfolio diversification, though risks include interest rate sensitivity and macroeconomic volatility affecting bond valuations.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
